OR WAIT null SECS
Parexel and NeoGenomics, Inc. have announced a partnership aiming to advance the application of precision medicine in oncology clinical trials by applying real-world genomics data.
The strategic partnership between Parexel and NeoGenomics will enable biopharmaceutical customers to make decisions regarding trial designs, companion diagnostics and drug repurposing as well as to build external control arms using genomic data. The companies are considering potential opportunities to expand the scope of the partnership, including lab services and biomarker capabilities.
For more information, click here.